Propranolol SR Pellets Manufacturer in India
Propranolol SR Pellets are pharmaceutical-grade sustained-release multiparticulate pellets designed for incorporation into oral dosage forms where a controlled release profile of propranolol is required. The pellet platform can be formulated using an active-containing core together with suitable release-controlling components to achieve the desired dissolution behavior.
For pharmaceutical pellet applications, the active ingredient is generally Propranolol Hydrochloride. Propranolol Hydrochloride has CAS Number 318-98-9, molecular formula C₁₆H₂₂ClNO₂, and molecular weight 295.80 g/mol. These values describe the active pharmaceutical ingredient and should not be confused with the active loading or assay of the finished pellets.
Commercial pellet references document different Propranolol SR pellet strengths. A commercial product portfolio lists 40% Propranolol SR Pellets, while other published commercial references document 47% Propranolol Hydrochloride pellets and a formulation-development example uses 20% active in the pellet core. These values demonstrate that active loading is formulation-specific. For SDP, the final strength should be entered according to the approved SDP specification rather than assuming a market strength.
Propranolol SR Pellets use multiparticulate technology to distribute the active ingredient across multiple individual pellets. A sustained-release coating or other release-controlling system can then regulate the movement of the active ingredient from the pellet matrix.
This formulation approach provides flexibility in controlling:
Published formulation-development work describes Propranolol sustained-release pellets prepared using a pellet core followed by a release-controlling polymer coating. A separate commercial product reference describes spherical Propranolol Hydrochloride pellets in a 14–20 mesh range. These characteristics are formulation-specific and should not automatically be treated as SDP specifications.
Propranolol SR pellet loading can vary considerably depending on the formulation design.
Published commercial examples include:
The 40% strength is documented in a commercial pellet portfolio, but it should only be presented as an SDP available strength if confirmed against the current SDP product specification.
Active loading is particularly important because it influences pellet composition, coating requirements, capsule fill weight, dissolution behavior and the amount of multiparticulate material required per dosage unit.
Propranolol SR Pellets are intended for sustained-release multiparticulate formulation development. The release-controlling system can be optimized according to the target dissolution profile and formulation requirements.
Potential applications include:
The final release profile should be established using the validated product-specific dissolution method.
Spherical multiparticulate pellets can provide useful flow and filling characteristics for capsule applications. Consistent pellet size and density can help support reproducible capsule fill weights.
Important pellet characteristics include:
Commercial Propranolol Hydrochloride pellet references specifically describe spherical pellets suitable for capsule and tablet formulation applications.
The sustained-release performance of Propranolol SR Pellets depends on the formulation and manufacturing process.
Important variables include:
A sustained-release coating can be designed to control the diffusion of Propranolol from the individual pellets and produce the required overall dissolution profile.
Finished-product dissolution limits should be specified according to the approved SDP product specification and should not be replaced by generic market values.
Accurate active loading and uniform distribution are important quality attributes for Propranolol SR Pellets.
The finished pellet specification should clearly distinguish between:
API specification:
The specification applicable to Propranolol Hydrochloride as the pharmaceutical ingredient.
Finished pellet specification:
The actual Propranolol loading, assay range, content uniformity, moisture, physical characteristics and release profile of the finished pellet.
Therefore, an API assay value should not be presented as the assay specification of the finished Propranolol SR Pellets.
Propranolol SR Pellets can be developed for multiparticulate formulations where controlled release and consistent pellet performance are required.
Formulation development may evaluate:
Process optimization is important because changes in pellet size, coating thickness, polymer level and active loading can affect the final release characteristics.
Swapnroop provides Propranolol SR Pellets for pharmaceutical formulation applications, with emphasis on sustained-release multiparticulate technology, controlled active loading, pellet characteristics and formulation requirements.
As a Propranolol SR Pellets Manufacturer in India, the product can be positioned for pharmaceutical formulation companies, formulation-development teams and bulk procurement requirements. Related search terms include Propranolol Hydrochloride SR Pellets, Propranolol Sustained Release Pellets, Propranolol Pharmaceutical Pellets, Propranolol SR Pellets Manufacturer India, Propranolol Pellets Supplier India, Propranolol Multiparticulate Pellets, Propranolol Controlled Release Pellets and Propranolol Capsule Filling Pellets.
Propranolol SR Pellets can be supplied according to approved product and customer requirements, including:
Available strengths and packaging configurations should be confirmed against the current SDP product specification.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Individual Impurity | NMT 0.5% |
| Water Content | NMT 1.0% |